Aggregation inhibitor that modulates the formation of pathological oligomers of both prion and α-synuclein.1 In mouse models of prion and diseases and Parkinson’s disease, Anle138b strongly inhibited oligomer formation, neuronal degeneration, and disease progression even after disease onset....
Know who made it. See the evidence. Buy through one marketplace.
Aggregation inhibitor that modulates the formation of pathological oligomers of both prion and α-synuclein.1 In mouse models of prion and diseases and Parkinson’s disease, Anle138b strongly inhibited oligomer formation, neuronal degeneration, and disease progression even after disease onset. Anle138b has delayed disease progression and prevented motor decline in multiple neurodegenerative models. Treatment of melanoma cells with anle138b caused massive cell death via major dysregulation of autophagy revealing a protective effect of α-synuclein on autophagy in these cells. Orally bioavailable and able to cross the blood-brain barrier
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
